Results 11 to 20 of about 39,378 (264)

The role of radiotherapy in locally advanced pancreatic cancer

The British Journal of Radiology, 2021
At diagnosis, about 15% of patients with pancreatic cancer present with a resectable tumour, 50% have a metastatic tumour, and 35% a locally advanced tumour, non-metastatic but unresectable due to vascular invasion, or borderline resectable. Despite the technical progress made in the field of radiation therapy and the improvement of the efficacy of ...
Huguet, Florence, Dabout, Victoire, Rivin del Campo, Eleonor, Gaujoux, Sébastien, Bachet, Jean Baptiste   +4 more
openaire   +3 more sources

Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial)

BMC Cancer, 2023
Background Locally advanced pancreatic ductal adenocarcinoma (PDAC), accounting for about 30% of PDAC patients, is difficult to cure by radical resection or systemic chemotherapy alone.
Osamu Shimomura, Masato Endo, Hirokazu Makishima, Takeshi Yamada, Shinji Hashimoto, Haruko Numajiri, Yoshihiro Miyazaki, Manami Doi, Kinji Furuya, Kazuhiro Takahashi, Toshikazu Moriwaki, Naoyuki Hasegawa, Yoshiyuki Yamamoto, Yusuke Niisato, Mariko Kobayashi, Masashi Mizumoto, Kei Nakai, Takashi Saito, Sodai Hoshiai, Tsukasa Saida, Bryan J. Mathis, Kensaku Mori, Takahito Nakajima, Kiichiro Tsuchiya, Hideyuki Sakurai, Tatsuya Oda   +25 more
doaj   +1 more source

Irreversible Electroporation for Locally Advanced Pancreatic Cancer [PDF]

Techniques in Vascular and Interventional Radiology, 2020
Several minimally invasive image guided tumor ablation techniques have been added to the treatment spectrum for locally advanced pancreatic cancer (LAPC). Irreversible electroporation (IRE) might have a significant additive value in the management of this difficult-to-treat disease.
Timmer, Florentine E.F., Geboers, Bart, Ruarus, Alette H., Schouten, Evelien A.C., Nieuwenhuizen, Sanne, Puijk, Robbert S., de Vries, Jan J.J., Meijerink, Martijn R., Scheffer, Hester J.   +8 more
openaire   +3 more sources

Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial

Clinical and Translational Radiation Oncology, 2022
Purpose: Addressing the epidermal growth factor receptor (EGFR)-pathway by the competitive receptor ligand cetuximab is a promising strategy in pancreatic cancer.
Jakob Liermann, Marc Munter, Patrick Naumann, Amir Abdollahi, Robert Krempien, Juergen Debus   +5 more
doaj   +1 more source

Irreversible electroporation of locally advanced pancreatic cancer

Seminars in Oncology, 2021
Locally advanced pancreatic cancer (LAPC) constitutes approximately one-third of all pancreatic cancer, with standard of care inconsistently defined and achieving modest outcomes at best. While resection after downstaging offers the chance for cure, only a fraction of patients with LAPC become candidates for resection. Chemotherapy remains the mainstay
Wooil Kwon, Alexander Thomas, Michael D. Kluger   +2 more
openaire   +2 more sources

Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma – results of the Conko-007 multicenter trial

BMC Cancer, 2019
Background One critical step in the therapy of patients with localized pancreatic cancer is the determination of local resectability. The decision between primary surgery versus upfront local or systemic cancer therapy seems especially to differ between ...
U. A. Wittel, D. Lubgan, M. Ghadimi, O. Belyaev, W. Uhl, W. O. Bechstein, R. Grützmann, W. M. Hohenberger, A. Schmid, L. Jacobasch, R. S. Croner, A. Reinacher-Schick, U. T. Hopt, A. Pirkl, H. Oettle, R. Fietkau, H. Golcher   +16 more
doaj   +1 more source

Locally Advanced Pancreatic Cancer

JOP : Journal of the pancreas, 2013
Treatment of locally advanced pancreatic cancer is palliative, based on chemotherapy and according to response, chemoradiotherapy can be applied. The authors summarize three abstracts (#LBA146, #256 and #303) presented on the 2013 ASCO Gastrointestinal Cancers Symposium, which were focused on treatment of locally advanced pancreatic cancer.
Georgios M, Oikonomopoulos, Kathryn E, Huber, Konstantinos N, Syrigos, Muhammad Wasif, Saif   +3 more
openaire   +2 more sources

Sequential Irreversible Electroporation for Locally Advanced Pancreatic Cancer

Diagnostics, 2023
Pancreatic cancer is a lethal disease, with locally advanced pancreatic cancer (LAPC) having a dismal prognosis. For patients with LAPC, gemcitabine-based regimens, with or without radiation, have long been the standard of care.
Daniel Yuxuan Ong, Uei Pua
doaj   +1 more source

Ablation Strategies for Locally Advanced Pancreatic Cancer [PDF]

Digestive Surgery, 2016
With the advent of novel and somewhat effective chemotherapy against pancreas cancer, several groups developed a new interest on locally advanced pancreatic cancer (LAPC). Unresectable tumors constitute up to 80% of pancreatic cancer (PC) at the time of diagnosis and are associated with a 5-year overall survival of less than 5%. To control those tumors
Linecker, Michael, Pfammatter, Thomas, Kambakamba, Patryk, DeOliveira, Michelle L   +3 more
openaire   +3 more sources

Locally Advanced Unresectable Pancreatic Cancer

JOP : Journal of the pancreas, 2014
Twenty-five percent of patients with pancreatic cancer present with locally advanced disease that is unresectable, and the treatment strategy for these patients is controversial, with options including chemotherapy alone, concurrent chemoradiation, or induction chemotherapy followed by chemoradiation. Abstracts presented at the 2014 American Society of
Kimberly L, Johung, Muhammad Wasif, Saif, Bryan W, Chang   +2 more
openaire   +2 more sources